(* represents equal contribution)

Published Papers (PDFs)

  1. Robinson M, Schor S, Barouch-Bentov R, and Einav S. Viruses and the intracellular roads more travelled by. Cellular and Molecular Life Sciences. 2018 July 24.
  2. Wouters R, Pu S, Schor S, Barouch-Bentov R, Brannan J, Dye J, Herdewijn P, De Jonghe S and Einav S. Optimization of isothiazolo[4,3-b]pyridines-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity. Journal of Medicinal Chemistry. 2018 June 28.(DOI: 10.1021/acs.jmedchem.8b00613)
  3. Pu S, Xiao F, Schor S, Bekerman E, Fabio Z, Barouch-Bentov R, Nagamine C and Einav S. Feasbility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Research. Volume 155, July 2018, Pages 67–75. 
  4. Barouch-Bentov R and Einav S. Turning Up Your Nose for a Flaviviral Encephalitis Cure. Cell Host & Microbe. 2018 Volume 23 , Issue 4 , 427 - 429
  5. Xiao F, Shulla A, Wang S, Pu S, Neveu G, Beer M, Schor S, Barouch-Bentov R, Randall G, and Einav SInteractions between the nonstructural 2 protein and host adaptor proteins 1 and 4 orchestrate hepatitis C virus release. mBio2018 Mar 13;9(2). pii: e02233-17. doi: 10.1128/mBio.02233-17.
  6. Zanini F*, Pu S*, Bekerman E, Einav S**, and Quake SR**. Single-cell transcriptional dynamics of flavivirus infection. eLife. Feb 2018.
  7. Schor S and Einav S. Combating intracellular pathogens with repurposed host-targeted drugs. American Chemical Society Infectious Diseases. 2018 Jan 3. doi: 10.1021/acsinfecdis.7b00268. [Epub ahead of print]. PMID: 29298032.
  8. Schor S and Einav S. Repurposing kinase inhibitors as broad-spectrum antiviral drugs. DNA and Cell Biology. 2017 Nov 17. doi: 10.1089/dna.2017.4033. PMID: 29148875.
  9. Bekermnan E*, Neveu G*, Shulla A, Brannan J, Pu SZ, Wang S, Xiao F, Barouch-Bentoc R, Bakken RR, Mateo R, Govero J, Nagamine C, Diamond M, De Jonghe S, Herdewijn P, Dye J, Randall G, and Einav S. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. Journal of Clinical Investigation. 2017 Feb 27. PMID: 28240606
  10. Barouch-Bentov R, Neveu G, Xia F, Beer M, Bekerman E, Schor S, Campbell J, Boonyaratanakornkit J, Lindenbach B, Lu A, Jacob Y, Einav S. Hepatitis C Virus Proteins Interact with the Endosomal Sorting Complex Required for Transport (ESCRT) Machinery via Ubiquitination To Facilitate Viral Envelopment. mBio. 2016 Nov 1;7(6). PMID: 27803188, PMCID: PMC5090039
  11. Glick Y,  Ben-Ari Y,  Drayman N, Pellach M, Neveu G, Boonyaratanakornkit J, Avrahami D, Einav S, Oppenheim A, Gerber D. Pathogen Receptor Discovery with a Microfluidic Human Membrane Protein Array. Proceedings of the National Academy of Sciences. 2016 Apr 19;113(16):4344-9. doi: 10.1073/pnas.1518698113. PMID: 27044079, PMCID: PMC4843447. 
  12. Plissonnier ML, Lahlali T, Michelet M, Lebossé F, Cottarel J, Beer M, Neveu G, Durantel D, Bartosch B, Accardi R, Clément S, Paradisi A, Devouassoux M, Einav S, Mehlen P, Zoulim F, Parent R. Epidermal Growth Factor Receptor-dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus. PLoS Biology. 2016 Mar 31;14(3):e1002421. doi: 10.1371/journal.pbio.1002421. PMID: 27031829. PMCID: PMC4816328.
  13. Li K, Kovackova S, Pu S, Rozenski J, De Jonghe S, Einav S, and Herdewijn P. Isothiazolo[4,3-b]pyridines as inhibitors of cyclin G associated kinase: synthesis, structure–activity relationship studies and antiviral activity. Medicinal Chemistry Communications. 2015 Aug.  
  14. Bekerman E, Einav S. Response—Applying antibiotics lessons to antivirals. Science. 2015 Jun 26; 348(6242):1437. PMID: 26113710.
  15. Bekerman E, Einav S. Combating Emerging Viral Threats. Science. 2015; 348(6232):282-3. PMID: 25883340.
  16. Neveu G, Ziv-Av A, Barouch-Bentov R, Berkerman E, Mulholland J, Einav S. AP-2-Associated Protein Kinase 1 and Cyclin G-Associated Kinase Regulate Hepatitis C Virus Entry and Are Potential Drug Targets. Journal of Virology. 2015; 89(8):4387-404. PMID: 25653444.
  17. Kovackova S, Chang L, Bekerman E, Neveu G, Barouch-Bentov R, Chaikuad A, Heroven C, Šála M, De Jonghe S, Knapp S, Einav S, Herdewijn P. Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents. Journal of Medicinal Chemistry. 2015; PMID: 25822739.
  18. Ng PP, Kuo CC, Wang S, Einav S, Aracaini L, Portlock CS, Marcotrigiano J, Tarr A, Ball J, Levy , and Levy S. B Cell Receptors Expressed by Lymphomas of Hepatitis C virus-Infected Patients Rarely React with the Viral Proteins. Blood. 2014 Jan 21. Epub. PMID: 24449209.
  19. Neveu G, Barouch-Bentov R, Ziv-Av A, Gerber D, Jacob Y, and Einav S. Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly. PLoS Pathogens. 2012 Aug 16; 8 (8): e1002845. PMID: 22916011.
  20. Einav S, Dvory-Sobol H, Gehrig H and Glenn JS. The Hepatitis C virus (HCV) NS4B RNA Binding Inhibitor, Clemizole, is Highly Synergistic with HCV Protease Inhibitors. Journal of Infectious Diseases. 2010 Jul 1;202(1):65-74. PMID: 20486856.
  21. Bryson BD, Cho NJ, Einav S, Lee CH, Tai V, Bechtel J, Sivaraja M, Roberts C, Schmitz U, Glenn JS. Small Molecule Inhibits HCV Replication and Disrupts NS4B Subcellular Localization. Antiviral Research. 2010 Apr 2. PMID: 20363257.
  22. Parameswaran P, Sklan HE, Burgon T, Samuel MA, Wilkins C, Lu R, Ansel KM,  Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, Babrzadeh F, Gharizadeh B, Grimm D, Kay M, Sarnow P, Ronaghi M, Ding SW, Harris E,  Chow M, Diamond MS, Kirkegaard K, Glenn JS, and Fire A. 6 RNA VIRUSES & 41 HOSTS: vsRNAs And Viral Modulation of Small Rna Repertoires in Vertebrate and Invertebrate Systems. PLoS Pathogens. 2010 Feb 12;6(2):e1000764. PMID: 20169186.
  23. Einav S*, Gerber D*, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR. Discovery of a Hepatitis C Target and its Pharmacological Inhibitors by Microfluidic Affinity Analysis. Nature Biotechnology. 2008 Sept 26 (9): 1019-27. PMID: 18758449. (+Journal Cover).
  24. Einav S, Sklan H E, Moon E, Gehrig E, Liu P, Hao Y, Lowe AW and Glenn JS.  The Nucleotide Binding Motif of Hepatitis C Virus NS4B Can Mediate NIH3T3 Transformation and Tumor Formation in the Absence of Activated Ha-ras Co-Transfection. Hepatology. 2008 Mar 47(3):827-35. PMID: 18081150.
  25. Sklan EH, Serrano RL, Einav S, Pfeffer SR, Lambright DG, Glenn JS. TBC1D20 is a Rab1 GAP that Mediates HCV Replication. Journal of Biological Chemistry. 2007 Dec 14; 282(50):36354-61. PMID: 17901050.
  26. Einav S*, Elazar M*, Danieli T, and Glenn JS. A Nucleotide Binding Motif in HCV NS4B Mediates HCV RNA Replication. Journal of Virology. 2004 Oct 78 (20):11288-95. PMID: 15452248.
  27. Einav S, Glenn JS. Prenylation Inhibitors: a Novel Class of Antiviral Agents. Journal of Antimicrobial Chemotherapy. 2003 November; 52: 883-886. Review. PMID: 14613953.
  28. Einav S, Koziel MJ. Immunopathogenesis of Hepatitis C in the Immunosuppressed host. Transplant Infectious Disease. 2002 June; 4(2):85-92. Review. PMID: 12220245.
  29. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is Protective for Lupus Disease Independent of C3. Journal of Immunology. 2002 Feb 1;168(3):1036-41. PMID: 11801636.

Book Chapters

Shafer RW, Einav S and Chou S (2007). Mechanisms of Resistance to Antiviral Agents. In Manual of Clinical Microbiology, 9th Edition, Murray PR ed, Baron EJ ed, Jorgensen JH ed, Pfaller MA ed, Tenover FC ed, and Yolken RH ed. American Society of Microbiology. 1689-04.


Clathrin adaptors orchestrate hepatitis C virus (HCV) trafficking during viral assembly and release (Manuscript resubmitted to PLoS Pathogens, work presented as a talk at the 21st International Symposium on HCV and Related Viruses).


De Jonghe S, Herdewijn P and Einav S. PCT filing, co-owned by Stanford and University of Leuven/Belgium, is currently pending. Antiviral use of GAK-modulators.

Einav S, Barouch-Bentov R, Neveu G, and Zivav A. Methods and compositions for treating viral diseases. WO 2013/086133.

Einav S, Barouch-Bentov R, Neveu G. Methods and compositions for treating enveloped viruses. US-2017-0136021-A1 (WO2016054468 A1).

Einav S, Glenn JS, Mcdowell R, Yang W. US 8895598. 2014 November 25. Methods of treating a Flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection. 

Glenn JS, Einav S. US 8871435. 2014 October 28. Methods and compositions for identifying agents that inhibit an NS4B-mediated neoplastic cellular phenotype of HCV infected cells

Einav S, Glenn JS, Mcdowell R, Yang W, Dvory-Sobol H. US 8895598. Nov 25th 2014. Methods of Treating a Flaviviridae Family Viral Infection, Compositions for Treating a Flaviviridae Family Viral Infection, and Screening Assays for Identifying Compositions for Treating a Flaviviridae Family Viral Infection.

Einav S, Glenn JS, Yang W, Dvory-Sobol H, Choong IC, McDowell R. US 20100028299. 2010 February 04. Methods and compositions of treating a flaviviridae family viral infection

Einav S, Glenn JS, Yang W, Dvory-Sobol H, Choong IC, McDowell R. US 20100015093. 2010 January 21. Methods and compositions of treating a flaviviridae family viral infection

Einav S, Glenn JS, McDowell R, Yang W, Dvory-Sobol H. US 20110052536. 2011 March 03. Methods of treating a flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection

Glenn JS, Einav S, Elazar M. US 20100203498. 2010 August 12. Methods and compositions for identifying anti-hcv agents.

Glenn JS, Einav S, Elazar M. United States US 7582428. 2009 September 01. Methods and compositions for identifying anti-HCV agents